(OCGN) Ocugen, Inc. Business Model Canvas Research

Ocugen, Inc. leans on contract development and manufacturing partners to run CMC, scale-up, and GMP quality work for its gene therapy programs, especially OCU400 and OCU410. That outside support is key for clinical supply now and for any commercial launch later, since viral-vector manufacturing is a hard, capital-heavy step.

• External CMC lowers build-out risk

• Supports scale-up and batch release

• Needed for clinical and commercial supply

Ocugen uses FDA-facing regulatory support and multi-site trial networks to get study approvals, run safety checks, and prepare submissions. In 2025, that network mattered most for its 2 lead gene-therapy programs, OCU400 and OCU410, which need site coverage and regulator alignment to move from early work into later-stage testing.

• FDA-ready trial setup
• Multi-site safety monitoring
• Supports later-stage filings

Ocugen, Inc. is advancing OCU200, a fusion protein in preclinical testing, for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. The work centers on lab testing, candidate optimization, and IND-enabling studies before any human trial can start.

• Preclinical fusion protein program
• Three retinal disease targets
• Focus: lab, optimization, IND-enabling work

Ocugen, Inc. must build chemistry, manufacturing, and controls (CMC) files, lock in GMP-ready manufacturing, and keep regulatory filings clean for its biologics pipeline. These steps protect clinical supply and are the gate to future approvals, because one gap in compliance can stall a program fast.

• CMC supports clinical batches
• Manufacturing plans reduce supply risk
• Regulatory work keeps approvals on track

Ocugen, Inc.’s CanSino and Bharat Biotech agreements are core contractual assets: they give the company access to manufacturing and development support, plus U.S. commercialization rights for COVAXIN. These licenses matter because they turn a small-cap biotech into a rights-holder with partner leverage, not just a developer.

• Access to external manufacturing
• U.S. commercialization rights for COVAXIN
• Lower upfront development burden
• Stronger future deal leverage

Ocugen, Inc. is headquartered in Malvern, Pennsylvania, and the site anchors corporate management, strategy, and administration. It also helps coordinate R&D, regulatory, and business development work across the Company, which reported $2.8 million in revenue and a $73.5 million net loss in 2025.

• Malvern hub for leadership
• Supports R&D and regulatory work
• Coordinates business development

Ocugen’s novel gene-therapy strategy aims to restore retinal function, not just slow vision loss, which gives it a longer-dated treatment profile than standard ophthalmic drugs. Its lead retinal program, OCU400, is built to target inherited retinal disease biology at the gene level, helping the Company stand apart from symptom-focused therapies.

• Targets root cause, not symptoms
• Supports durable treatment potential
• Differs from conventional eye drugs

Bharat Biotech gives Ocugen, Inc. a U.S. commercialization route for COVAXIN, creating a non-dilutive option outside its core eye-disease pipeline. It adds one more value driver to the business mix and can reduce dependence on a single therapeutic area.

• U.S. path for COVAXIN
• Non-dilutive growth option
• Diversifies long-term value

Ocugen, Inc. runs partner-managed B2B ties, so commercial and manufacturing work sits in formal agreements, not direct customer service. Two named partners, CanSino and Bharat Biotech, show how the model depends on collaboration, licensing, and shared execution across products and markets.

• 2 key partner links: CanSino, Bharat Biotech
• Deal-led, not consumer-facing
• Focus: manufacturing and commercial execution

Ocugen keeps frequent contact with investors and analysts through quarterly earnings calls, SEC filings, and pipeline updates. For a clinical-stage biotech, clear disclosure on trial progress, cash use, and financing needs is key to market trust and access to capital.

• Quarterly earnings calls
• SEC filings and disclosures
• Pipeline and trial updates
• Supports financing confidence

Ocugen, Inc. depends on the FDA and other regulators as a must-pass channel for every lead program, because it has no approved commercial product yet and sales only begin after formal review, clearance, and labeling decisions. In 2025, that meant each meeting, filing, and milestone acted as a gate for future revenue, not just a compliance step.

• FDA review unlocks market access
• Formal submissions move programs forward
• Milestones gate future sales

Ocugen, Inc. uses press releases, SEC filings, and investor presentations to keep the market updated on pipeline milestones, clinical data, and funding needs. For a development-stage biotech with no broad commercial launch, that flow matters because it supports trust while the Company funds R&D and manages dilution risk.

• Shares pipeline progress fast
• Explains financing needs clearly
• Keeps investors informed

Patients with wet AMD are a large, high-need segment because neovascular age-related macular degeneration can rapidly damage central vision and often needs repeated anti-VEGF injections. OCU200’s potential relevance here matters because vision preservation is the main clinical goal, and even small gains in durability can cut visit burden.

• High unmet need
• Repeated treatment demand
• Vision-preservation focus

Healthcare systems and public health buyers would be the main institutional customers for COVAXIN in the United States, not retail patients. This segment buys through hospital systems, state programs, and procurement teams, and it sits apart from Ocugen, Inc.'s ophthalmology pipeline.

• Institutional purchasing, not consumer demand

• Includes hospital systems and public buyers

• Separate from ophthalmology assets

Ocugen, Inc.’s general and administrative costs cover payroll, finance, legal, and headquarters ops, and its Malvern, Pennsylvania base supports day-to-day governance. As a Nasdaq-listed biotech, Ocugen also carries recurring SEC, audit, and board compliance costs, so this line stays tied to public-company scale rather than product volume.

• Payroll and HQ overhead
• Finance and legal support
• Malvern administration hub
• Ongoing public-company compliance

Ocugen, Inc. spends on FDA filings, outside regulatory advice, and patent protection to keep its gene-therapy and biologic programs exclusive while pushing approvals through long review cycles. These costs matter because the Company’s pipeline can take years to clear trials, so IP defense and regulatory work stay a fixed part of the model.

• Files and maintains patents.
• Pays for regulatory counsel.
• Supports long approval cycles.

OCU200 could become a future revenue stream if Ocugen, Inc. turns it into an approved biologic, but it is still pre-commercial, so there is no product sales revenue yet. Its focus on multiple retinal diseases could widen the addressable market and add a second future product line alongside Ocugen, Inc.'s other assets.

• Pre-commercial today
• Potential biologic sales later
• Broader retinal disease reach

The Bharat Biotech alliance gives Ocugen, Inc. a potential U.S. vaccine revenue line from COVAXIN through sales, distribution, or licensing-style commercial deals. Any such income would sit outside the ophthalmic pipeline, and as of the latest public reporting Ocugen has not yet built material vaccine sales into its revenue base.

• Possible U.S. vaccine sales revenue
• Can include distribution fees
• Can include commercial partnership payments
• Separate from eye-disease programs